DCT

3:26-cv-09635

Astellas Pharma Inc v. Macleods Pharma Ltd

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 3:26-cv-09635, D.N.J., 07/30/2026
  • Venue Allegations: Venue is alleged to be proper as to Macleods Ltd. because it is a foreign corporation. Venue is alleged to be proper as to Macleods Inc. based on its principal place of business in New Jersey, its registration with New Jersey state agencies, and its engagement in activities within the state relevant to the submission of the Abbreviated New Drug Application (ANDA) at issue.
  • Core Dispute: Plaintiffs allege that Defendants’ filing of an ANDA to market generic versions of the prostate cancer drug Xtandi® (enzalutamide) infringes four U.S. patents covering formulations and methods of use for the drug.
  • Technical Context: The technology concerns pharmaceutical formulations of enzalutamide, an androgen receptor signaling inhibitor, designed to improve the drug's poor solubility and oral bioavailability for the treatment of prostate cancer.
  • Key Procedural History: This action arises under the Hatch-Waxman Act, triggered by Defendants' submission of ANDA No. 221507 with a Paragraph IV certification challenging the asserted patents. Plaintiffs filed this complaint within the 45-day window following receipt of Defendants' notice letter. The complaint notes a related action pending in the District of New Jersey against a different generic manufacturer, Astellas Pharma Inc v. DR Reddy's Laboratories Inc et al.

Case Timeline

Date Event
2012-09-11 Earliest Priority Date for ’689, ’357, and ’128 Patents
2015-08-12 Earliest Priority Date for ’628 Patent
2016-09-28 Pfizer Inc. acquires Medivation, Inc.
2017-08-28 Medivation entities convert to LLCs
2020-08-04 FDA approves NDA No. 213674 for Xtandi® tablets
2023-11-16 FDA approves expanded indication for Xtandi® tablets
2023-12-12 U.S. Patent No. 11,839,689 Issues
2024-12-10 U.S. Patent No. 12,161,628 Issues
2025-10-21 U.S. Patent No. 12,447,128 Issues
2025-12-23 U.S. Patent No. 12,502,357 Issues
2026-06-15 Date of Macleods' Notice Letter to Plaintiffs
2026-07-30 Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 11,839,689 - "Formulations of Enzalutamide"

  • Patent Identification: U.S. Patent No. 11,839,689, "Formulations of Enzalutamide," issued December 12, 2023 Compl. ¶26

The Invention Explained

  • Problem Addressed: The patent addresses the poor aqueous solubility and absorption of the cancer-treating agent enzalutamide, which limits its oral bioavailability ’689 Patent, col. 2:20-24
  • The Patented Solution: The invention is a pharmaceutical composition containing a "solid dispersion" of amorphous enzalutamide with a "concentration-enhancing polymer," specifically hydroxypropyl methylcellulose acetate succinate (HPMCAS) ’689 Patent, abstract This formulation allows the poorly soluble drug to be maintained in an amorphous (non-crystalline) state, which dissolves more quickly and achieves a higher concentration in the body compared to its crystalline form, thereby improving its oral bioavailability ’689 Patent, col. 2:48-54 Compl. ¶25 The complaint provides a visual of the chemical structure for enzalutamide Compl. ¶25
  • Technical Importance: Creating stable, effective oral dosage forms for poorly soluble drugs is a significant challenge in pharmaceutical development, and solid dispersion technology represents a key method for enhancing bioavailability.

Key Claims at a Glance

  • The complaint asserts infringement of at least Claim 1 (Compl. Prayer B; Compl. ¶52).
  • Independent Claim 1 of the ’689 Patent recites the following essential elements:
    • A pharmaceutical composition
    • comprising a solid dispersion
    • consisting essentially of amorphous enzalutamide
    • and hydroxypropyl methylcellulose acetate succinate (HPMCAS).
  • The complaint notes that certain dependent claims specify the formulation is a tablet Compl. ¶52

U.S. Patent No. 12,161,628 - "Combination Therapy"

  • Patent Identification: U.S. Patent No. 12,161,628, "Combination Therapy," issued December 10, 2024 Compl. ¶28

The Invention Explained

  • Problem Addressed: The patent addresses a drug-drug interaction where co-administration of enzalutamide with a "strong CYP3A4 inducer," such as the antibiotic rifampin, can significantly decrease the plasma concentration of enzalutamide and its active metabolite ’628 Patent, col. 2:5-9
  • The Patented Solution: The invention provides a specific method for overcoming this interaction by increasing the daily dose of enzalutamide. The patent claims a method of treating prostate cancer in a patient also taking rifampin by co-administering an increased daily dose of 240 mg of enzalutamide, higher than the standard 160 mg dose ’628 Patent, abstract ’628 Patent, col. 2:10-19
  • Technical Importance: The invention provides a precise dosing instruction to manage a clinically significant drug-drug interaction, allowing patients to maintain therapeutic drug levels while receiving necessary concomitant medications ’628 Patent, col. 2:10-19

Key Claims at a Glance

  • The complaint asserts infringement of at least Claim 1 of the ’628 Patent Compl. ¶67 Compl. ¶68
  • Independent Claim 1 of the ’628 Patent recites the following essential elements:
    • A method of treating prostate cancer in a patient to whom rifampin is administered,
    • comprising co-administering to the patient a daily dose of 240 mg of enzalutamide.

U.S. Patent No. 12,502,357 - "Formulations of Enzalutamide"

  • Patent Identification: U.S. Patent No. 12,502,357, "Formulations of Enzalutamide," issued December 23, 2025 Compl. ¶30
  • Technology Synopsis: This patent claims a method of treating prostate cancer by administering a tablet that contains a solid dispersion comprising amorphous enzalutamide and HPMCAS. This method applies the formulation technology of the '689 patent—of which the '357 patent is a continuation—to a specific therapeutic application ’357 Patent Compl. ¶80
  • Asserted Claims: Independent Claim 1 is asserted Compl. ¶80
  • Accused Features: The accused features are Macleods' proposed generic tablets, which are alleged to contain a solid dispersion of amorphous enzalutamide and HPMCAS and will be indicated for treating prostate cancer Compl. ¶¶82-84

U.S. Patent No. 12,447,128 - "Formulations of Enzalutamide"

  • Patent Identification: U.S. Patent No. 12,447,128, "Formulations of Enzalutamide," issued October 21, 2025 Compl. ¶32
  • Technology Synopsis: This patent claims a method of treating prostate cancer by administering two tablets, each comprising a spray-dried dispersion of 80 mg amorphous enzalutamide and 400 mg HPMCAS. A key aspect of the invention is a stability requirement: the enzalutamide must remain amorphous after being stored at 40°C and 75% relative humidity for one month Compl. ¶99
  • Asserted Claims: Claim 3 is asserted Compl. ¶99
  • Accused Features: Macleods' proposed 80 mg generic tablets are accused of infringing. The complaint alleges that the generic tablets will meet the claimed composition, dosage, and stability requirements Compl. ¶102

III. The Accused Instrumentality

Product Identification

  • The accused products are Defendants' proposed 40 mg and 80 mg generic enzalutamide tablets, for which Defendants filed ANDA No. 221507 seeking FDA approval Compl. ¶¶40-41

Functionality and Market Context

  • The accused products are intended to be generic equivalents of Plaintiffs' Xtandi® tablets, used for the treatment of castration-resistant prostate cancer, metastatic castration-sensitive prostate cancer, and non-metastatic castration-sensitive prostate cancer Compl. ¶42
  • The complaint alleges that the accused generic products, if approved, will contain a pharmaceutical composition comprising a solid dispersion of amorphous enzalutamide and HPMCAS, thereby allegedly copying the formulation of Xtandi® Compl. ¶55 Compl. ¶57 Compl. ¶83 The complaint further alleges that the proposed product labeling will instruct use for the same indications as Xtandi®, including instructions for dosage adjustments when co-administered with drugs like rifampin Compl. ¶69 Compl. ¶87 Compl. ¶106

IV. Analysis of Infringement Allegations

11,839,689 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
a pharmaceutical composition comprising a solid dispersion consisting essentially of amorphous enzalutamide and hydroxypropyl methylcellulose acetate succinate The complaint alleges that Macleods' Generic Products will contain a pharmaceutical composition comprising a solid dispersion consisting essentially of amorphous enzalutamide and HPMCAS or an equivalent thereof. ¶57 col. 3:46-49

12,161,628 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A method of treating prostate cancer in a patient to whom rifampin is administered, The proposed labeling for Macleods' Generic Products will allegedly direct its use for treating prostate cancer and identify rifampin as a strong CYP3A4 inducer that interacts with enzalutamide. ¶69 col. 2:9-14
comprising co-administering to the patient a daily dose of 240 mg of enzalutamide. The proposed labeling will allegedly direct the co-administration of the generic product at a dose of 240 mg orally once daily in patients who are receiving rifampin. ¶69 col. 2:9-13
  • Identified Points of Contention:
    • Scope Questions ('689, '128 Patents): The complaint alleges the accused product will contain the claimed solid dispersion "or an equivalent thereof" Compl. ¶57 Compl. ¶83 Compl. ¶102 This language raises the question of whether Defendants' formulation will be identical to the one claimed or will contain additional excipients. The analysis will likely focus on whether any such additional ingredients materially affect the "basic and novel properties" of the invention, which is the legal standard for the claim term "consisting essentially of."
    • Technical Questions ('128 Patent): Claim 3 of the '128 Patent includes a functional limitation requiring that the amorphous enzalutamide "remains amorphous" after storage for one month at 40° C. and 75% relative humidity Compl. ¶99 A point of contention may be what evidence is required to prove that the proposed generic product will meet this stability requirement before it is commercially manufactured and sold.
    • Legal Questions ('628, '357, '128 Patents): For the asserted method-of-treatment claims, the complaint pleads artificial infringement under 35 U.S.C. § 271(e)(2)(A) as to the '628, '357, and '128 patents, induced infringement under § 271(b), and contributory infringement under § 271(c) as to the '357 and '128 patents. A central legal question will be whether the proposed product label, by providing indications and dosage instructions, actively encourages and promotes an infringing use, or merely provides information about a known drug interaction and safety-based dose adjustments.

V. Key Claim Terms for Construction

  • The Term: "consisting essentially of" (from Claim 1 of the '689 Patent)
  • Context and Importance: This transitional phrase is critical for defining the scope of the composition claims. Its construction will determine whether Defendants' generic formulation, which the complaint suggests may be the claimed dispersion "or an equivalent thereof" Compl. ¶57, falls within the claims. Practitioners may focus on this term because the dispute will likely center on whether any additional, unlisted excipients in the generic product "materially affect the basic and novel properties" of the invention—namely, the enhanced solubility and bioavailability derived from the specific combination of amorphous enzalutamide and HPMCAS.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The specification's primary focus is on the combination of amorphous enzalutamide and a concentration-enhancing polymer to solve the solubility problem ’689 Patent, col. 2:20-24 ’689 Patent, col. 3:46-49 A party could argue that as long as additional excipients are inert and do not interfere with this primary function, they do not materially affect the invention's properties.
    • Evidence for a Narrower Interpretation: The patent's abstract and independent claim recite the specific pairing of amorphous enzalutamide with HPMCAS as the claimed composition ’689 Patent, abstract A party could argue that this specific combination is the core of the invention and that any additional substance that could potentially impact dissolution kinetics, stability, or the amorphous state would be a material alteration.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges induced infringement for the '628, '357, and '128 patents. The basis for these allegations is that Defendants' proposed product labeling will instruct and encourage physicians and patients to use the generic drug in a manner that directly practices the steps of the claimed methods of treatment Compl. ¶69 Compl. ¶87 Compl. ¶106 For the '357 and '128 patents, the complaint also alleges contributory infringement, asserting the generic product is especially made for an infringing use and is not a staple article of commerce suitable for substantial non-infringing use Compl. ¶93 Compl. ¶112
  • Willful Infringement: The complaint alleges that Defendants knew of the asserted patents through their listing in the FDA's Orange Book and as acknowledged in their own Paragraph IV notice letter Compl. ¶59 Compl. ¶65 Compl. ¶86 Compl. ¶105 It further claims that Defendants' assertions of invalidity and non-infringement are "devoid of an objective good faith basis," and that the case is "exceptional," which forms the basis for a request for attorneys' fees under 35 U.S.C. § 285 Compl. ¶61 Compl. ¶76 Compl. ¶95 Compl. ¶114 Compl. Prayer E

VII. Analyst’s Conclusion: Key Questions for the Case

  • A core issue will be one of formulation scope: can the term "consisting essentially of" be construed to cover Defendants' proposed generic formulation? This determination will likely depend on a factual analysis of whether any unlisted excipients in the generic product materially alter the key bioavailability-enhancing characteristics of the claimed amorphous solid dispersion Compl. ¶57
  • A second central question will be one of inducement by labeling: does the language in Defendants' proposed product label, which allegedly provides specific dosage instructions for the claimed indications, constitute active encouragement of infringement, or does it merely convey information to physicians, falling short of the legal standard for inducement?
  • A key evidentiary question will be one of predictive functionality: what evidence will be required to establish that Defendants' ANDA product, prior to its commercial launch, will meet the specific functional and stability requirements of the patent claims, such as the requirement in the ’128 Patent that the enzalutamide remains amorphous after storage under defined stress conditions?